| Literature DB >> 24982923 |
Malihe Khoeini Sharifabadi1, Mohammad Saber-Tehrani1, Syed Waqif Husain1, Ali Mehdinia2, Parviz Aberoomand-Azar1.
Abstract
A simple and sensitive solid-phase extraction method for separation and preconcentration of trace amount of four nonsteroidal anti-inflammatory drugs (naproxen, indomethacin, diclofenac, and ibuprofen) using Fe3O4 magnetic nanoparticles modified with cetyltrimethylammonium bromide has been developed. For this purpose, the surface of MNPs was modified with cetyltrimethylammonium bromide (CTAB) as a cationic surfactant. Effects of different parameters influencing the extraction efficiency of drugs including the pH, amount of salt, shaking time, eluent type, the volume of solvent, amount of adsorbent, sample volume, and the time of desorption were investigated and optimized. Methanol has been used as desorption solvent and the extracts were analysed on a reversed-phase octadecyl silica column using 0.02 M phosphate-buffer (pH = 6.02) acetonitrile (65 : 35 v/v) as the mobile phase and the effluents were measured at 202 nm with ultraviolet detector. The relative standard deviation (RSD%) of the method was investigated at three concentrations (25, 50, and 200 ng/mL) and was in the range of 3.98-9.83% (n = 6) for 50 ng/mL. The calibration curves obtained for studied drugs show reasonable linearity (R (2) > 0.99) and the limit of detection (LODs) ranged between 2 and 7 ng/mL. Finally, the proposed method has been effectively employed in extraction and determination of the drugs in biological and environmental samples.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24982923 PMCID: PMC4058801 DOI: 10.1155/2014/127835
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Figure 1The TEM image of the synthesized MNPs, magnification 160000.
Figure 2Adsorption efficiency of CTAB-coated MNPs as a function of samples pH.
Figure 3The adsorption performance of nonsteroidal anti-inflammatory drugs as a function of the amount of CTAB added.
Analytical characteristics of SPE based on CATB-coated MNPs for the determination of nonsteroidal anti-inflammatory drugs.
| Analyte | LOD (ngmL−1)a |
| Regression equation | LDR (ngmL−1)b | PF | ER% |
|---|---|---|---|---|---|---|
| DICLO | 7 | 0.997 |
| 10–200 | 36.70 | 91.76 |
| INDO | 2 | 0.996 |
| 2.5–400 | 38.49 | 96.24 |
| IBU | 3 | 0.999 |
| 5–400 | 37.74 | 94.36 |
| NAP | 2 | 0.999 |
| 10–400 | 38.04 | 95.11 |
aLimit of detection.
bLinear dynamic range.
Average relative standard deviation (RSD) for spiked drugs (n = 6).
| Analyte | 25 ng·mL−1 | 50 ng·mL−1 | 200 ng·mL−1 |
|---|---|---|---|
| DICLO | 10.94% | 9.83% | 8.16% |
| INDO | 7.02% | 6.61% | 4.45% |
| IBU | 5.86% | 3.98% | 3.85% |
| NAP | 5.53% | 4.11% | 3.73% |
Comparison of the proposed method with other analytical methods for the determination of different nonsteroidal anti-inflammatory drugs in various samples.
| Analytical technique | Matrix | Linear range |
| LOD | ER% | RSD% | Reference |
|---|---|---|---|---|---|---|---|
| HFLPME-HPLC (Ibu-Diclo) | Urine | (135–10000) ng/mL | >0.99 | (41–53) ngmL−1 | 99% | [ | |
| SPME-HPLC (Ibu) | Urine | (5–50) | >0.98 | 5 | (3.7–5.7) % | <13.4 | [ |
| Supra molecular SPE-LC (Nap-Ibu) | Sewage | Ibu (0.2–750) ng | >0.99 | 0.8 ngmL−1
| (93–101) % | (2–9) % | [ |
| SPE-LC (Diclo-Indo) | Urine | (0.02–1.0) | >0.99 | 0.007–0.035 | (85-85) % | Diclo (0.95–9.8) % | [ |
| MSPE-HPLC (NSAIDs) | Urine and sewage | (7–200) ng/mL | >0.99 | (2–7) ng/mL | (91.76–96.24) % | (3.98–9.83) % | This work |
SPME: solid phase micro extraction; SPE: solid phase extraction; HFLPME: hollow fiber liquid phase microextraction; MNPs: magnetic nanoparticles.
Determination of the INDO in wastewater and INDO, IBU in urine samples.
| Sample | INDo | IBu |
|---|---|---|
| (1) Inlet of wastewater | ||
| Initial concentration ( | 1.91 | — |
| RSD% | 6.41 | — |
|
(2) Inlet of wastewater | ||
| Found | 25.83 | — |
| RSD% | 5.24 | — |
| Preconcentration factor | 38.39 | — |
| (3) Outlet of wastewater | ||
| Initial concentration ( | — | |
|
(4) Outlet of wastewater | ||
| Found | 24.71 | — |
| RSD% | 4.93 | — |
| Preconcentration factor | 39.53 | — |
|
(5) Urine (patient) | ||
| Initial concentration ( | 10.10 | 689.89 |
| Found | 107.61 | 751.37 |
| RSD % | 4.11 | 1.70 |
| Preconcentration factor | 39.09 | 38.05 |
|
(6) Urine | ||
| Initial concentration | — | — |
| Found | 100.07 | 97.45 |
| RSD% | 4.66 | 3.93 |
| Preconcentration factor | 40.02 | 38.98 |
Figure 4Chromatograms for nonsteroidal anti-inflammatory drugs (a) in a patient urine sample and (b) in a spike patient urine sample at 100 μgL−1.
Figure 5Chromatograms for nonsteroidal anti-inflammatory drugs (a) in an outlet wastewater and (b) in a spike outlet wastewater sample at 25 μg L−1.